Pacer Advisors Inc. Sells 5,110 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Pacer Advisors reduced its Alnylam Pharmaceuticals stake by 53.3% in the first quarter, selling 5,110 shares and retaining 4,478 shares valued at $1.48 million. Hedge funds and other institutional investors own 92.97% of the company.
• Director David E. I. Pyott sold 3,830 shares for approximately $1.15 million under a pre-arranged Rule 10b5-1 plan, reducing his direct holdings by 70.77%.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and average price target of $396.72, though several firms recently lowered their targets. ALNY opened at $219.20, well below its 12-month high of $495.55.

Pacer Advisors Inc. cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,478 shares of the biopharmaceutical company's stock after selling 5,110 shares during the period. Pacer Advisors Inc.'s holdings in Alnylam Pharmaceuticals were worth $1,482,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its position in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 175 shares during the period. Flow Traders U.S. LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $241,000. Daiwa Securities Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock valued at $4,220,000 after purchasing an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company's stock worth $229,000 after purchasing an additional 703 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company's stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.4%

Shares of ALNY opened at $219.20 on Friday. The firm has a fifty day moving average price of $280.12 and a 200-day moving average price of $306.27. The company has a current ratio of 3.05, a quick ratio of 3.06 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $29.33 billion, a P/E ratio of 40.74 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $455 price target. Although the firm lowered its 2026, 2028, 2029 and 2030 EPS forecasts, it raised its FY2027 estimate to $9.50 from $8.13, signaling expectations for continued longer-term earnings growth. HC Wainwright estimates for Alnylam Pharmaceuticals
• Neutral Sentiment: Several HC Wainwright revisions reduced projected EPS, including Q3 2026 to $1.65 from $1.79, Q4 2026 to $1.97 from $2.23, and FY2026 to $6.30 from $6.51. The firm’s estimates remain broadly positive beyond 2026, reaching $19.42 per share by FY2030, but the near-term reductions could limit enthusiasm. Alnylam Pharmaceuticals earnings estimates
• Neutral Sentiment: An AAII comparison examines whether Alnylam or Halozyme Therapeutics is the more attractive investment. The article may influence investor preferences, but it does not identify a new company-specific operating catalyst. Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. Stock?
• Neutral Sentiment: Options-market implied volatility for ALNY has surged, pointing to increased expectations for price movement and trading risk rather than a clear bullish or bearish fundamental signal. Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
• Negative Sentiment: Truist Financial lowered its price target on Alnylam to $315, a more cautious valuation view that could weigh on the stock and reflects concern about the company’s risk-reward profile. Truist Financial Lowers Alnylam Pharmaceuticals Price Target

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Stifel Nicolaus lowered their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Sanford C. Bernstein upgraded shares of Alnylam Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, July 29th. Oppenheimer reduced their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 31st. Finally, Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $396.72.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source